This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Ataxia telangiectasia mutated (ATM); c-Met proto-oncogene (MET; HGFR); p53	<p>Computational pathway analysis and a cell-based genomewide small hairpin RNA screen suggest inhibition of ATM or MET could improve the efficacy of the small molecule p53 pathway activator Nutlin-3 in cancer. In a 3D multicellular tumor spheroid model, Nutlin-3 plus an ATM or MET inhibitor completely ablated all tumor spheroids, whereas Nutlin-3 alone only decreased spheroid growth. Next steps could include testing the combination therapies in mouse models of cancer.</p> <p>R7112, a nutlin Mdm2 p53 binding protein homolog (MDM2; HDM2) antagonist from Roche, is in Phase I trials to treat cancer.</p> <p>SciBX 5(25); doi:10.1038/scibx.2012.649 Published online June 21, 2012</p>	Patent and licensing status unavailable	<p>Sullivan, K.D. <i>et al. Nat. Chem. Biol.</i>; published online June 3, 2012; doi:10.1038/nchembio.965</p> <p>Contact: Joaquín M. Espinosa, University of Colorado at Boulder, Boulder, Colo. e-mail: joaquin.espinosa@colorado.edu</p>